Unilever Ventures Invests in Novos, Focusing on Longevity Science
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 05 2026
0mins
Should l Buy UL?
Source: Yahoo Finance
- Investment Partnership: Unilever Ventures has acquired a minority stake in longevity biotech company Novos, reflecting a shared belief in science-led approaches to longevity, which is expected to drive further development of Novos in the nutraceuticals sector.
- R&D Achievements: Novos' flagship product, Novos Core, successfully extended the lifespan of aged mice by over 18% in animal studies and demonstrated significant improvements in cardiovascular health during clinical trials, particularly in enhancing vascular dilation capacity, indicating its effectiveness and market potential.
- Clinical Trial Advantages: In a double-blind, randomized controlled trial at the University of Surrey, Novos Core improved flow-mediated dilation (FMD) by 2.6 to 2.9 percentage points, far exceeding the effects typically seen with other supplements, showcasing its leading position in scientific validation.
- Market Expansion: Novos is currently sold directly to consumers in 180 countries and is available in the U.S. at retailers such as the Mayo Clinic store, Erewhon in Los Angeles, and select Four Seasons and Equinox gyms, with expectations to drive sales growth through increased consumer awareness.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy UL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on UL
Wall Street analysts forecast UL stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 56.900
Low
60.10
Averages
68.37
High
74.00
Current: 56.900
Low
60.10
Averages
68.37
High
74.00
About UL
Unilever PLC is a United Kingdom-based global consumer goods business. The Company's segments include Beauty & Wellbeing, Personal Care, Home Care and Foods. The Beauty & Wellbeing segment primarily sells hair care (shampoo, conditioner, styling), skin care (face, hand and body moisturizers) and includes Prestige Beauty and Wellbeing. The Personal Care segment primarily sells skin cleansing (soap, shower), deodorant and oral care (toothpaste, toothbrush, mouthwash) products. The Home Care segment primarily sells fabric care (washing powders and liquids, rinse conditioners) and a range of home and hygiene cleaning products. The Foods segment primarily sells cooking aids and mini-meals (soups, bouillons, seasonings), condiments (mayonnaise, ketchup) and Unilever Food Solutions. The Company's beauty & wellbeing brands include CLEAR, Dermalogica, Liquid I.V., Dove and TRESemme. The Company's home care brands include Cif, Comfort, Domestos, OMO, Radiant, Sunlight and Surf.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Strong Sales Performance: Unilever reported Q1 sales of €12.6 billion, exceeding market expectations despite a 3.3% decline in reported sales due to currency headwinds, while underlying growth reached 3.8% for the three months ending March 31, showcasing the company's resilience in challenging conditions.
- Core Brand Strength: The company's Power Brands achieved a 5.0% underlying sales growth, with 4.0% attributed to volume increases, indicating sustained consumer demand and further solidifying Unilever's competitive position in the market.
- Emerging Markets Lead Growth: Underlying sales in emerging markets rose by 5.7%, driven by 4.2% from volume and 1.5% from price, with India delivering a notable 7% growth, highlighting the consumption potential and market opportunities in these regions.
- Optimistic Future Outlook: Unilever expects FY2026 underlying sales growth at the low end of its 4%-6% range, with at least 2% volume growth, while also anticipating a modest improvement in operating margin from 20.0% in 2025, reflecting the company's confidence in future performance.
See More
- Market Opening Expectations: European stocks are anticipated to open lower, with the UK's FTSE index down 0.1%, Germany's DAX down 0.7%, France's CAC 40 down 0.5%, and Italy's FTSE MIB down 0.7%, reflecting investor sensitivity to geopolitical risks amid ongoing tensions in Iran.
- Surge in Oil Prices: Brent crude oil prices surged 6.84% to $126.10 per barrel, reaching a wartime high due to reports that the U.S. military would brief President Trump on potential military actions against Iran, indicating market concerns over supply disruptions.
- Central Bank Policy Focus: The European Central Bank and the Bank of England are set to announce their latest monetary policy decisions today, with no interest rate changes expected; however, their forward guidance will be closely monitored for potential economic implications amid the ongoing conflict.
- Earnings Release Day: A busy day for earnings reports includes major companies like Schneider Electric, Unilever, and Volkswagen, with the market evaluating the impact of these results on economic outlooks, particularly in the current uncertain macroeconomic environment.
See More
- Significant Growth: L'Oreal's organic sales rose 7.6% year-over-year to €12.2 billion ($14.3 billion) in Q1, significantly exceeding analysts' expectations of 3-4%, indicating robust vitality in the beauty market.
- Market Share Gains: CEO Nicolas Hieronimus stated that the company not only outperformed a dynamic beauty market but also accelerated market share growth globally, particularly excelling in e-commerce channels in emerging markets.
- Successful Acquisition Strategy: Last month, L'Oreal completed the acquisition of Kering Beauté for €4 billion, further solidifying its position in the high-growth health and beauty care sector, demonstrating proactive engagement in industry consolidation.
- Growth Across Divisions: Despite being the smallest unit, the professional products division saw a 13.1% like-for-like sales increase, indicating that the company achieved growth across cosmetics, haircare, skincare, and perfumes, enhancing its competitive edge in the market.
See More
- Rating Upgrade: RBC Capital Markets upgraded Unilever (UL) from Underperform to Sector Perform, with analyst James Edwardes Jones noting that market concerns regarding the divestiture of Unilever's food business are fairly reflected in the current stock price.
- Cautious Growth Outlook: While management aims to increase Unilever's exposure to high-growth categories, the analyst team questions the public growth aspirations compared to more subdued targets, suggesting that the competitive positioning of the resulting business will remain unchanged.
- Uncertain Shareholder Benefits: Looking ahead, Edwardes Jones highlighted that during the period when Unilever retains ownership of its food business, the experience from the ice cream divestment indicates that shareholders may not necessarily benefit post-divestment.
- Price Target Set: RBC Capital Markets set a price target of £42 for Unilever (UL) based on earnings estimates that fall below consensus expectations, reflecting a cautious stance on the company's future performance, especially as shares have declined over 11% year-to-date.
See More
- Dividend Increase: Procter & Gamble raised its quarterly dividend from $1.0568 to $1.0885 per share, resulting in an annual payout of $4.354 and a forward yield of 3%, reflecting the company's ongoing commitment to shareholder returns.
- Dividend King Status: This increase positions P&G among only five companies that have raised dividends for over 70 consecutive years, further solidifying its status as a Dividend King and attracting income-focused investors.
- Market Competitiveness: As the largest household and personal products company globally, P&G demonstrates resilience with an operating margin exceeding 20%, despite facing consumer spending challenges, showcasing its ability to maintain stability during economic fluctuations.
- Investment Opportunity: The recent stock sell-off has pushed P&G's dividend yield to a five-year high, with a price-to-earnings ratio of 21.4 and a forward P/E of 20.8, presenting an attractive buying opportunity for value investors looking to anchor their passive income portfolios.
See More
- Dividend Increase: Procter & Gamble raised its quarterly dividend from $1.0568 to $1.0885 per share, resulting in an annual payout of $4.354 and a forward yield of 3%, demonstrating the company's resilience amid economic slowdowns.
- Industry Position: As the largest household and personal products company globally, P&G ranks third in market capitalization among U.S. consumer staples, trailing only Walmart and Costco, highlighting its strong competitive edge in the market.
- Financial Health: With earnings per share at $6.75 and free cash flow at $6.09, P&G maintains a solid dividend payout ratio of 61.9%, indicating robust financial health while sustaining dividend growth.
- Market Adaptability: Despite consumer spending challenges, P&G effectively offsets weak performance in North America by leveraging a diversified product portfolio and geographic flexibility, ensuring continued growth in the global market.
See More











